Jump to content

Pegvaliase

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Anypodetos (talk | contribs) at 19:24, 24 December 2019 (New ATC code; navbox; stub sorting). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pegvaliase
Clinical data
Trade namesPalynziq
Other namesPegvaliase-pqpz; PEG-PAL; RAvPAL-PEG
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
  • (2S)-2-amino-6-[6-(2-methoxyethoxy)hexanamido]hexanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
3D model (JSmol)
  • COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O
  • InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1
  • Key:NPOCDVAOUKODSQ-ZDUSSCGKSA-N

Pegvaliase (trade name Palynziq) is a medication for the treatment of the genetic disease phenylketonuria.[2] Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.[3]

It was approved by the Food and Drug Administration for use in the United States in 2018.[2]

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ a b "FDA approves a new treatment for PKU, a rare and serious genetic disease". Food and Drug Administration. May 24, 2018.
  3. ^ "Palynziq". BioMarin Pharmaceutica.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pegvaliase&oldid=932287711"